Company Profile
BrightPath Biotherapeutics develops cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer.
Its portfolio also includes BP2202, Phase I clinical trial to target cancer, and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers.
In addition, its product candidates in preclinical trials include BP1200 that targets CD73. Its portfolio also includes BP1202 that targets CD39, BP1210, which suppresses T cell cytotoxicity, BP1212 to inhibit TIM-3 and CD39, BP1209 to target tumor-specific neoantigens, and BP1223 to target blood cancers. Incorporated in 2003 and headquartered in Kawasaki, Japan, the company was formerly known as GreenPeptide Co., Ltd. before rebranding in July 2017.